Cargando…

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

BACKGROUND: In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Braman, Nathaniel M., Etesami, Maryam, Prasanna, Prateek, Dubchuk, Christina, Gilmore, Hannah, Tiwari, Pallavi, Pletcha, Donna, Madabhushi, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437672/
https://www.ncbi.nlm.nih.gov/pubmed/28521821
http://dx.doi.org/10.1186/s13058-017-0846-1
_version_ 1783237637735186432
author Braman, Nathaniel M.
Etesami, Maryam
Prasanna, Prateek
Dubchuk, Christina
Gilmore, Hannah
Tiwari, Pallavi
Pletcha, Donna
Madabhushi, Anant
author_facet Braman, Nathaniel M.
Etesami, Maryam
Prasanna, Prateek
Dubchuk, Christina
Gilmore, Hannah
Tiwari, Pallavi
Pletcha, Donna
Madabhushi, Anant
author_sort Braman, Nathaniel M.
collection PubMed
description BACKGROUND: In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). METHODS: A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases. Feature selection was used to identify a set of top pCR-associated features from within a training set (n = 78), which were then used to train multiple machine learning classifiers to predict the likelihood of pCR for a given patient. Classifiers were then independently tested on 39 patients. Experiments were repeated separately among hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR(+), HER2(−)) and triple-negative or HER2(+) (TN/HER2(+)) tumors via threefold cross-validation to determine whether receptor status-specific analysis could improve classification performance. RESULTS: Among all patients, a combined intratumoral and peritumoral radiomic feature set yielded a maximum AUC of 0.78 ± 0.030 within the training set and 0.74 within the independent testing set using a diagonal linear discriminant analysis (DLDA) classifier. Receptor status-specific feature discovery and classification enabled improved prediction of pCR, yielding maximum AUCs of 0.83 ± 0.025 within the HR(+), HER2(−) group using DLDA and 0.93 ± 0.018 within the TN/HER2(+) group using a naive Bayes classifier. In HR(+), HER2(−) breast cancers, non-pCR was characterized by elevated peritumoral heterogeneity during initial contrast enhancement. However, TN/HER2(+) tumors were best characterized by a speckled enhancement pattern within the peritumoral region of nonresponders. Radiomic features were found to strongly predict pCR independent of choice of classifier, suggesting their robustness as response predictors. CONCLUSIONS: Through a combined intratumoral and peritumoral radiomics approach, we could successfully predict pCR to NAC from pretreatment breast DCE-MRI, both with and without a priori knowledge of receptor status. Further, our findings suggest that the radiomic features most predictive of response vary across different receptor subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-017-0846-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5437672
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54376722017-05-22 Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI Braman, Nathaniel M. Etesami, Maryam Prasanna, Prateek Dubchuk, Christina Gilmore, Hannah Tiwari, Pallavi Pletcha, Donna Madabhushi, Anant Breast Cancer Res Research Article BACKGROUND: In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). METHODS: A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases. Feature selection was used to identify a set of top pCR-associated features from within a training set (n = 78), which were then used to train multiple machine learning classifiers to predict the likelihood of pCR for a given patient. Classifiers were then independently tested on 39 patients. Experiments were repeated separately among hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR(+), HER2(−)) and triple-negative or HER2(+) (TN/HER2(+)) tumors via threefold cross-validation to determine whether receptor status-specific analysis could improve classification performance. RESULTS: Among all patients, a combined intratumoral and peritumoral radiomic feature set yielded a maximum AUC of 0.78 ± 0.030 within the training set and 0.74 within the independent testing set using a diagonal linear discriminant analysis (DLDA) classifier. Receptor status-specific feature discovery and classification enabled improved prediction of pCR, yielding maximum AUCs of 0.83 ± 0.025 within the HR(+), HER2(−) group using DLDA and 0.93 ± 0.018 within the TN/HER2(+) group using a naive Bayes classifier. In HR(+), HER2(−) breast cancers, non-pCR was characterized by elevated peritumoral heterogeneity during initial contrast enhancement. However, TN/HER2(+) tumors were best characterized by a speckled enhancement pattern within the peritumoral region of nonresponders. Radiomic features were found to strongly predict pCR independent of choice of classifier, suggesting their robustness as response predictors. CONCLUSIONS: Through a combined intratumoral and peritumoral radiomics approach, we could successfully predict pCR to NAC from pretreatment breast DCE-MRI, both with and without a priori knowledge of receptor status. Further, our findings suggest that the radiomic features most predictive of response vary across different receptor subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-017-0846-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-18 2017 /pmc/articles/PMC5437672/ /pubmed/28521821 http://dx.doi.org/10.1186/s13058-017-0846-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Braman, Nathaniel M.
Etesami, Maryam
Prasanna, Prateek
Dubchuk, Christina
Gilmore, Hannah
Tiwari, Pallavi
Pletcha, Donna
Madabhushi, Anant
Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
title Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
title_full Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
title_fullStr Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
title_full_unstemmed Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
title_short Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
title_sort intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast dce-mri
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437672/
https://www.ncbi.nlm.nih.gov/pubmed/28521821
http://dx.doi.org/10.1186/s13058-017-0846-1
work_keys_str_mv AT bramannathanielm intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT etesamimaryam intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT prasannaprateek intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT dubchukchristina intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT gilmorehannah intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT tiwaripallavi intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT pletchadonna intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri
AT madabhushianant intratumoralandperitumoralradiomicsforthepretreatmentpredictionofpathologicalcompleteresponsetoneoadjuvantchemotherapybasedonbreastdcemri